AscellaHealth Recognized in SHSMD Calendar of Healthcare Observances for Gene Therapy and Specialty Pharmacy Awareness Month

BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance the quality of life for patients with complex, chronic conditions, announces its third consecutive year of continued support for Gene Therapy and Specialty Pharmacy Awareness Month, designated in the Calendar of Healthcare Observances & Recognition Days that is published by the Society for Health Care Strategy & Market Development (SHSMD) of the American Hospital Association (AHA). For more information, visit the SHSMD Calendar of Health Observances & Recognition Days here.

“We invite all stakeholders in the specialty pharmaceutical industry to join us in raising awareness and strengthening the understanding of innovative gene therapies and specialty medications for complex, chronic and rare conditions,” says Dea Belazi, CEO of AscellaHealth. “During this month-long observance, we have a unique opportunity to spotlight the critical role of patient-centric care in optimizing treatment outcomes and enhancing the quality of life for patients and families.”

With a dedication to advancing the patient experience, AscellaHealth is deeply rooted in its commitment to innovative market access strategies that ensure patients receive the right therapies at the right time, regardless of cost or complexity. By partnering with biopharmaceutical manufacturers, payers, and healthcare providers, AscellaHealth develops solutions that overcome obstacles to accessing expensive gene therapies and specialty medications. These efforts include strategic market access initiatives centered on affordability, supply chain optimization, and leveraging real-world evidence to inform payer reimbursement decisions.

“AscellaHealth expects to draw attention to the value of specialty pharmacies, their focus on delivering high-cost medication therapy and providing high touch, coordinated care for patients with these complex conditions,” continues Belazi. “We will also continue to emphasize collaboration among manufacturers and public and private payers to improve patient access to therapy.”

Extending its support and commitment to the industry, AscellaHealth will attend the Self-Insurance Institute of America, Inc. (SIIA) National Conference, September 22-24, 2024, in Phoenix, AZ. Team leaders will meet with attendees to demonstrate the value of AscellaHealth’s end-to-end solutions, enhancing self-insured employers' ability to manage their specialty drug spend while optimizing therapeutic outcomes.

To arrange a meeting at SIIA, contact [e-mail].

About AscellaHealth LLC

AscellaHealth is a global partner that delivers proven end-to-end solutions to both life sciences and healthcare companies to enhance quality of life for patients with complex, chronic conditions. A dedicated team gets critical healthcare products from manufacturers to patients while ensuring an efficient flow of funds between payers and pharma. Visit www.AscellaHealth.com.